Mr. Henry is Senior Vice President, Clinical Operations at Fate Therapeutics and is responsible for the global implementation of the company’s clinical programs. He has over 35 years of experience managing clinical trials in global life science companies. Over the last decade, he has worked at the executive team level as the Sr. Vice President overseeing the Clinical Development Operations and Portfolio Management at several clinical-stage biotech companies delivering global programs in cell therapies, devices, and small molecules for Alcoholic Hepatitis, Becker Muscular Dystrophy, as well as Oncology portfolios. Mr. Henry has overseen large multi-million-dollar programs and portfolios across multiple therapeutic areas and has built and managed teams from 5 to 150 employees. At Schering-Plough Oncology, he was a part of the team that led to the approval of Temozolomide for treating brain cancers including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). At Novartis Oncology, he led the joint clinical team in partnership with Schering AG, developing an early antiangiogenic compound in a global Phase 3 colorectal cancer program. Mr. Henry has a B.S. in Biology with Honors in Biopsychology and Behavioral Genetics from William Paterson University.
